FDA Approves Gwyn Lo Birth Control Patch: A New Low-Dose Weekly Contraceptive Option for Women
The U.S. Food and Drug Administration (FDA) has approved Gwyn Lo, a new once-weekly hormonal contraceptive patch designed to provide women with another convenient and reversible birth control option. Developed by Viatris Inc., Gwyn Lo combines two hormones, norelgestromin and ethinyl estradiol, in a low-dose estrogen patch intended for women who are suitable candidates for combined hormonal contraception.
The approval represents a new development in women’s health by expanding contraceptive choices beyond daily pills, implants, injections, and intrauterine devices. With its once-weekly application schedule, Gwyn Lo may appeal to women who prefer a non-invasive method that does not require daily medication reminders.
What Is Gwyn Lo Birth Control Patch?
Gwyn Lo is a combined hormonal contraceptive (CHC) patch that delivers norelgestromin 220 mcg per day and ethinyl estradiol 20 mcg per day through the skin. The patch is designed to release hormones steadily during each seven-day wear period.
The contraceptive patch follows a weekly schedule. Users apply one patch each week for three consecutive weeks, followed by one patch-free week. This schedule is intended to provide pregnancy prevention while reducing the need for daily contraceptive management.
The FDA approval applies to women of childbearing potential with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for combined hormonal contraception.
Why the Approval of Gwyn Lo Matters
Access to a wide range of contraceptive options is important because women have different health needs, lifestyles, and preferences. Some women prefer methods that require daily attention, while others seek longer-lasting or lower-maintenance options.
Unintended pregnancy continues to be a significant public health concern in the United States. According to referenced national health data, unintended pregnancies represented a substantial portion of pregnancies in recent years. Research has also shown that many women change or discontinue contraceptive methods because they experience concerns, side effects, or dissatisfaction with their current option.
Gwyn Lo provides another choice for women looking for a reversible, non-invasive contraceptive method with a low estrogen dose.
Clinical Trial Results Supporting FDA Approval
The FDA approval of Gwyn Lo was supported by results from the Phase 3 Luminous Study, a clinical trial evaluating contraceptive effectiveness, safety, and patch performance.
The study measured contraceptive effectiveness using the Pearl Index, which estimates the number of pregnancies occurring per 100 woman-years of exposure. Among women included in the efficacy evaluation group, the Pearl Index was reported as 4.14 with a 95% confidence interval of 2.77 to 5.95.
Researchers also evaluated how well the patch remained attached during everyday activities. During the year-long study, 39,790 patches were applied, and only 1.3% completely detached. This finding demonstrated strong patch adhesion performance under real-world conditions.
The study also monitored common side effects. Reported adverse reactions occurring in at least 2% of participants included:
• Application site irritation
• Skin redness at the application area
• Application site itching
• Bleeding between menstrual cycles
• Heavy withdrawal bleeding
• Nausea
Researchers observed improvements in cycle control over time. Rates of unscheduled bleeding or spotting decreased from 34.5% during the first cycle to 20% by cycle 13. The average duration of these episodes also declined.
How Does Gwyn Lo Work?
Gwyn Lo works by releasing synthetic versions of estrogen and progestin hormones through the skin. These hormones help prevent pregnancy primarily by stopping ovulation. They may also change cervical mucus, making it more difficult for sperm to reach an egg, and alter the uterine lining.
The patch uses a multilayer matrix design. The active ingredients and adhesive are contained within a flexible structure that supports controlled hormone delivery throughout the seven-day application period.
Additional Phase 1 studies evaluated patch performance under different conditions, including exercise, sauna exposure, whirlpool use, and cold-water bathing. These studies showed consistent hormone delivery across different environments.
Important Safety Information About Gwyn Lo
Like other combined hormonal contraceptives, Gwyn Lo may not be suitable for everyone. Women should discuss their medical history and individual risk factors with a healthcare provider before starting this medication.
The FDA labeling states that Gwyn Lo is contraindicated for women who smoke and are over 35 years old because of an increased risk of serious cardiovascular events. The product is also contraindicated for women with a BMI of 30 kg/m² or higher.
Women should seek medical advice before using any hormonal contraceptive, especially if they have a history of blood clots, cardiovascular conditions, certain cancers, liver problems, or other medical concerns.
Availability of Gwyn Lo
Viatris announced that Gwyn Lo is expected to become commercially available later in the year following FDA approval. The company stated that the product reflects its continued focus on developing healthcare solutions, including innovations in women’s health.
The introduction of Gwyn Lo adds another option to the growing range of contraceptive methods available to women in the United States.
The Future of Contraceptive Options
The approval of new contraceptive technologies highlights the continued demand for flexible and personalized reproductive healthcare choices. While some women prefer long-acting methods, others may value methods that offer control, convenience, and easy discontinuation.
Weekly contraceptive patches like Gwyn Lo may provide an alternative for women who want the effectiveness of hormonal contraception without taking a daily pill.
As healthcare providers and patients continue discussing contraceptive options, access to accurate information remains essential for making informed decisions.
Conclusion
The FDA approval of Gwyn Lo marks an important step in expanding available birth control choices for eligible women. As a once-weekly, low-dose estrogen contraceptive patch, Gwyn Lo offers a convenient and reversible option for women seeking an alternative to daily contraceptive methods.
Although the patch provides a new option, choosing a contraceptive method should always involve a discussion with a qualified healthcare professional. Individual health history, lifestyle, and personal preferences all play an important role in selecting the most appropriate method.
Sources
- Viatris Inc. FDA approval announcement for Gwyn Lo (norelgestromin and ethinyl estradiol transdermal system), July 29, 2026.
- Rossen LM, Hamilton BE, Abma JC, Gregory ECW, Beresovsky V, Resendez AV, et al. Updated methodology to estimate overall and unintended pregnancy rates in the United States. National Center for Health Statistics. Vital and Health Statistics, Series 2, No. 201, 2023.
- National Center for Health Statistics. NCHS Rapid Surveys System: Contraception Use.
Disclaimer
This article is for informational and educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or contraceptive method. Individual results and suitability may vary depending on personal health conditions and medical history.